Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPAND: Cetuximab in Advanced Gastric Cancer
NCT00678535Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Jun 2008
- Primary completion
- Mar 2012
- Modality
- Monoclonal Antibodies
- Countries
- 25
01
Overview
A Phase 3 trial of KL-140 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Merck KGaA. Started Jun 2008; status: completed.
02
Drugs
KL-140
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT00678535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00678535.